Ling, Rod
Giles, Michelle
Searles, Andrew
Funding for this research was provided by:
Translational Research Grant Scheme (566955, 566955)
Article History
Received: 10 February 2021
Accepted: 22 July 2021
First Online: 31 August 2021
Declarations
:
: The study was granted ethical approval by the Hunter New England Human Research Ethics Committee (Ref no. 16/02/17/4.09) and the University of Newcastle Human Research Ethics Committee (Ref no. H-2016-0123) and carried out in accordance with the principles of the Declaration of Helsinki. Given that patients were receiving routine care in alignment with best practice principles in relation to IDC usage, the ethics committees deemed that consent was not required from patients. The trial was also registered retrospectively with the Australian New Zealand Clinical Trials Registry (ACTRN12617000090314 (17 January 2017, (retrospectively)). The first hospital enrolment was at 15/11/2016; while the last enrolment was at 8/12/2016.[CitationRef removed] [CitationRef removed] The study adhered to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and Consolidated Standards of Reporting Trials (STROBE) guidelines (Additional Files InternalRef removed and InternalRef removed). The original effectiveness study[CitationRef removed] was performed in conformance with the StaRI checklist.
: Not applicable.
: All authors have completed the unified completing interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.